Global Fair Pricing Tensions

Posted by Ed Schoonveld on Thu, May 16, 2019

Pricing for prescription drugs has been a contentious issue around the world as payers and patients don’t understand the cause of high drug prices and are struggling with patient access. Particularly in middle- and low-income countries, affordability of drugs in cancer has become an important part of a dialogue between the World Health Organization, governments, non-governmental organizations and patient advocates. The WHO has organized several meetings to explore and drive resolutions for drug-pricing-related issues for patented and generic drugs.


>
Read More

Dangerous, Simple Drug Pricing Solutions

Posted by Ed Schoonveld on Thu, Mar 21, 2019

At a time when drug company CEOs are questioned in Congress and polarized U.S. Democrats and Republicans appear to unite in an intent to act on drug pricing, the industry needs to be very concerned. U.S. politicians and academics are exploring ways to satisfy public thirst for lower drug cost. The biggest danger in today’s Twitter world is the appeal of seemingly simple solutions such as a single-payer system, international price index, ICER and, recently, a three-part pricing model.


>
Read More

Designing a Value Strategy

Posted by Ed Schoonveld on Thu, Mar 07, 2019

How do we use the access journey framework to design a winning value strategy in the age of value and affordability?


>
Read More

Who Cares?

Posted by Ed Schoonveld on Tue, Feb 12, 2019

In my recent post, I described the underlying changes that are leading to today’s payer-empowered pharmaceutical environment. Now let’s consider the implications of these changes on the negotiation process.


>
Read More

The Age of Value and Affordability

Posted by Ed Schoonveld on Wed, Jan 23, 2019

In last week’s blog, I argued that the pharmaceutical industry needs to take action to address recent drastic changes in the environment. Here’s a closer look at these underlying changes:


>
Read More